Enliven has converted a Phase one, part B data readout into a de facto Phase 3 green light, and the market has re-rated the stock roughly 2.5x off the January low in response. The June update at the European Hematology Association congress pushed the cumulative major molecular response rate to 61% in the recommended-dose cohort. The company also locked in alignment with the FDA on the dose and the 2L+ trial population. The company now sits on $895 million in cash after a $460 million public offering, giving it a runway into the next fiscal decade without further dilution. The stock closed at $59.37 as of the most recent session, implying a market capitalization near $4.35 billion.
That multiple reflects a market that is pricing in a successful Phase 3 and some share gain, not a binary option. The risk/reward has compressed relative to where it stood in January, but the fundamental inflection is real: Enliven has moved from a speculative pipeline story to a late-stage development company with a defined regulatory path. The central question is no longer whether the drug works, but whether it works well enough to displace incumbents in a crowded CML market.